Formulation and optimization of celecoxib-loaded PLGA nanoparticles by the Taguchi design and their in vitro cytotoxicity for lung cancer therapy

References

• Leahy M, Ornbrg RL, Wang Y, et al. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002;62:625–631
   PubMed Web of Science ®Google Scholar
• Trifan OC, Hla T. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med 2003;7:207–222
   PubMed Web of Science ®Google Scholar
• Smith WL, Garavito M, DeWitt DL. Prostaglandin endoperoxide H synthase (cyclooxygenase)-1 and 2. J Biol Chem 1996;271:33157–33160
   PubMed Web of Science ®Google Scholar
• Kargman SL, O’Neill GP, Vickers PJ, et al. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995;55:2556–2559
   PubMed Web of Science ®Google Scholar
• Liu XH, Rose DP. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res 1996;56:5125–5127
   PubMed Web of Science ®Google Scholar
• Decker MK, Furstenberger G. The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis. Mol Carcinog 2007;46:705–710
   PubMedGoogle Scholar
• Restimaki A, Honkanen N, Jankala H, et al. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57:1276–1280
   PubMedGoogle Scholar
• Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett’s esophagus and associated adenocarcinomas. Cancer Res 1998;58:2929–2934
   PubMed Web of Science ®Google Scholar
• Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997–5001
   PubMed Web of Science ®Google Scholar
• Deininger MH, Weller M, Streffer J, et al. Patterns of cyclooxygenase-1 and 2 expression in human gliomas in vivo. Acta Neuropathol 1999;98:240–244
   PubMed Web of Science ®Google Scholar
• Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705–716
   PubMed Web of Science ®Google Scholar
• Molina MA, Sitja-Arnau M, Lemoine MG, et al. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999;59:4356–4362
   PubMed Web of Science ®Google Scholar
• Elder DJ, Halton DE, Hague A, Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 1997;3:1679–1683
   PubMed Web of Science ®Google Scholar
• Liu XH, Yao S, Kirschenbaum A, Levine AC. NS-398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998;58:4245–4249
   PubMed Web of Science ®Google Scholar
• Hida T, Kozaki KI, Muramatsu H, et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000;6:2006–2011
   PubMed Web of Science ®Google Scholar
• Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7:861–867
   PubMed Web of Science ®Google Scholar
• Hida T, Leyton J, Makheja AN, et al. Nonsmall cell lung cancer cyclooxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs. Anticancer Res 1990;18:775–782
   Google Scholar
• Haynes A, Shaik MS, Chatterjee A, Singh M. Evaluation of an aerosolized selective COX-2 inhibitor as a potentiator of doxorubicin in non-small cell lung cancer cell line. Pharm Res 2003;20:1485–1495
   PubMed Web of Science ®Google Scholar
• Haynes A, Shaik MS, Chatterjee A, Singh M. Formulation and evaluation of aerosolized celecoxib for the treatment of lung cancer. Pharm Res 2005;22:427–431
   PubMedGoogle Scholar
• Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New Engl J Med 2005;352:1071–1080
   PubMed Web of Science ®Google Scholar
• Walker JE, Odden AR, Jeyaseelan S, et al. Ethanol exposure impairs LPS-induced pulmonary LIX expression: alveolar epithelial cell dysfunction as a consequence of acute intoxication. Alcohol Clin Exp Res 2009;33:357–365
   PubMedGoogle Scholar
• Haynes A, Shaik MS. Treatment of lung cancer. Pharm Res 2005;22:427–439
   PubMedGoogle Scholar
• Fulzele SV, Chatterjee A, Shaik MS, et al. Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograf model. Pharm Res 2006;23:2094–2106
   PubMed Web of Science ®Google Scholar
• Thakkar H, Sharma RK, Murthy RSR. Enhanced retention of celecoxib-loaded solid lipid nanoparticles after intra-articular administration. Drugs R D 2007;8:275–285
   PubMedGoogle Scholar
• Brophy JM. Celecoxib and cardiovascular risks. Expert Opin Drug Saf 2005;4:1005–1015
   PubMedGoogle Scholar
• Patlolla RR, Chougule M, Patel AR, et al. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release 2010;144:233–241
   PubMed Web of Science ®Google Scholar
• Makino K, Yamamoto N, Higuchi K, et al. Phagocytic uptake of polystyrene microspheres by alveolar macrophages: effects of the size and surface properties of the microspheres. Colloids Surf Biointerfaces 2003;27:33–39
   Web of Science ®Google Scholar
• Hoet P, Bruske-Hohlfeld I, Salata OV. Nanoparticles, known and unknown health risks. J Nanobiotechnol 2004;2:1–15
   PubMedGoogle Scholar
• Emami J, Hamishehkar H, Rouholamini Najafabadi A, et al. Particle size design of PLGA microspheres for potential pulmonary drug delivery using response surface methodology. J Microencapsul 2009;26:1–8
   PubMed Web of Science ®Google Scholar
• Emami J, Hamishehkar H, Rouholamini Najafabadi A, et al. A novel approach to prepare insulin-loaded poly (lactic-co-glycolic acid) microcapsules and the protein stability study. J Pharm Sci 2009;98:1712–1731
   PubMed Web of Science ®Google Scholar
• Hamishehkar H, Emami J, Najafabadi AR, et al. Pharmacokinetics and pharmacodynamics of controlled release insulin loaded PLGA microcapsules using dry powder inhaler in diabetic rats. Biopharm Drug Dispos 2010;31:189–201
   PubMed Web of Science ®Google Scholar
• Ahlin P, Kristl J, Kristl A. Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration. Int J Pharm 2002;239:113–120
   PubMed Web of Science ®Google Scholar
• Horisawa E, Hirota T, Kawazoe S. Prolonged anti-inflammatory action of DL-lactide/glycolide copolymer nanospheres containing betamethazone sodium phosphate for an intra-articular delivery system in antigen-induced arthritic rabbit. Pharm Res 2002;19:403–410
   PubMed Web of Science ®Google Scholar
• Dailey LA, Schmehl T, Gessler T. Nebulization of biodegradable nanoparticles, impact of nebulizer technology and nanoparticle characteristics on aerosol features. J Control Release 2003;86:131–144
   PubMed Web of Science ®Google Scholar
• Kim TH, Jeong YI, Jin SG, et al. Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells. Int J Nanomed 2011;6:2621–2631
   PubMed Web of Science ®Google Scholar
• McCarron PA, Donnelly RF, Marouf W. Celecoxib-loaded poly(D,L-lactide-co-glycolide) nanoparticles prepared using a novel and controllable combination of diffusion and emulsification steps as part of the salting-out procedure. J Microencapsul 2006;23:480–498
   PubMed Web of Science ®Google Scholar
• Timsina MP, Martin GP, Marriott C, et al. Drug delivery to the respiratory tract using dry powder inhalers. Int J Pharm 1994;101:1–13
   Web of Science ®Google Scholar
• Todo H, Okamoto H, Iida K, Danjo K. Effect of additives on insulin absorption from intratracheally administered dry powders in rats. Int J Pharm 2001;220:101–110
   PubMed Web of Science ®Google Scholar
• Schiavone H, Palakodaty S, Clark A, York P. Evaluation of SCF engineered particle-based lactose blends in passive dry powder inhalers. Int J Pharm 2004;281:55–66
   PubMed Web of Science ®Google Scholar
• Sahooa SK, Panyama J, Prabhaa S, Labhasetwara V. Residual polyvinyl alcohol associated with poly (D,L-lactide-coglycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 2002;82:105–114
   PubMedGoogle Scholar
• Wu TH, Yen FL, Lin LT, et al. Preparation, physicochemical characterization, and antioxidant effects of quercetin nanoparticles. Int J Pharm 2008;346:160–168
   PubMed Web of Science ®Google Scholar
• Mainardes RM, Evangelista RC. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm 2005;290:137–144
   PubMed Web of Science ®Google Scholar
• Chaisria W, Henninkb WE, Okonogia S. Preparation and characterization of cephalexin loaded PLGA microspheres. Curr Drug Deliv 2009;6:69–75
   PubMedGoogle Scholar
• Yang A, Yang L, Liu W, et al. Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: preparation and in vitro evaluation. Int J Pharm 2007;331:123–132
   PubMed Web of Science ®Google Scholar
• Oh DH, Balakrishnan P, Oh YK, et al. Effect of process parameters on nanoemulsion droplet size and distribution in SPG membrane emulsification. Int J Pharm 2011;404:191–197
   PubMed Web of Science ®Google Scholar
• Mukherjee B, Santra K, Pattnaik G, Ghosh S. Preparation, characterization and in-vitro evaluation of sustained release protein-loaded nanoparticles based on biodegradable polymers. Int J Nanomed 2008;3:487–496
   PubMed Web of Science ®Google Scholar
• Wiśniewska M. The temperature effect on electro kinetic properties of the silica–polyvinyl alcohol (PVA) system. Colloid Polym Sci 2011;289:341–344
   PubMedGoogle Scholar
• Choi Y, Joo JR, Hong A, Park JS. Development of drug-loaded PLGA microparticles with different release patterns for prolonged drug delivery. Bull Korean Chem Soc 2011;32:867–890
   Google Scholar
• Karatas A, Sonakin O, Kilicarslsn M, Baykara T. Effects of stirring rate and drug: polymer ratio on the characteristics of Levobunolol HCL loaded poly (e-Caprolactone) microparticles. Turk J Pharm Sci 2010;7:225–236
   Google Scholar
• Zhou S, Sun J, Sun L, et al. Preparation and characterization of interferon-loaded magnetic biodegradable microspheres. J Biomed Mater Res Part B: Appl Biomater 2008;87B:189–196
   Google Scholar
• Kushwaha P, Fareed S, Nanda S, Mishra A. Design and fabrication of tramadol HCl loaded multiparticulate colon targeted drug delivery system. J Chem Pharm Res 2011;3:584–595
   Google Scholar
• Derakhshandeh K, Nikmohammadi M, Hosseinalizadeh A. Factorial effect of process parameters on pharmaceutical characteristics of biodegradable PLGA microparticles. Int J Drug Del 2011;3:324–334
   Google Scholar
• Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci 2006;47:1149–1160
   PubMed Web of Science ®Google Scholar
• Zeini D, Khoshkenar P, Rabiee M. The influence of formulation and process parameters on the morphology, size and release profile of L-Dopa-loaded poly lactic-co-glycolic acid (PLGA) microspheres. Open Conference Proc J 2012;3:1–7
   Google Scholar
• Mainardes RM, Gremião MPD, Evangelista RC. Thermoanalytical study of praziquantel-loaded PLGA nanoparticles. Braz J Pharm Sci 2006;42:523–530
   Google Scholar
• Bozdağ-Pehlivan S, Subaşi B, Vural I, et al. Evaluation of drug-excipient interaction in the formulation of celecoxib tablets. Acta Pol Pharm Drug Res 2011;68:423–433
   PubMed Web of Science ®Google Scholar
• Sudhamani SR, Prasad MS, Udaya Sankar K. DSC and FTIR studies on Gellan and polyvinyl alcohol (PVA) blend films. Food Hydrocolloids 2003;17:245–250
   Web of Science ®Google Scholar
• Raju CL, Rao JL, Reddy BCV, Brahmam KV. Thermal and IR studies on copper doped polyvinyl alcohol. Bull Mater Sci 2007;30:215–218
   Web of Science ®Google Scholar
• Mukerjee A, Vishwanatha JK. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res 2009;29:3867–3876
   PubMed Web of Science ®Google Scholar
• Jo HS, Zhang Y, Finlay WH, et al. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm 2004;269:457–467
   PubMedGoogle Scholar
• Grenha A, Seijo B, Serra C, Lopez CR. Chitosan nanoparticle-loaded mannitol microspheres: structure and surface characterization. Biomacromolecules 2007;8:2072–2079
   PubMed Web of Science ®Google Scholar
• Grenha A, Lopez CR, Els C, Seijo B. Microspheres containing lipid/chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins. Eur J Phar Biopharm 2008;69:83–93
   PubMed Web of Science ®Google Scholar